跳至主要内容
临床试验/NCT02056171
NCT02056171终止1 期

Efficacy of Quetiapine for Pediatric Delirium

Weill Medical College of Cornell University2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
6
试验地点
2
主要终点
Time to First Resolution of Delirium

研究概览

简要总结

This study is designed to assess the safety and efficacy of quetiapine as treatment for pediatric delirium.

详细描述

Many children in the ICU become confused, due to their underlying illness or treatment effects. The medical term for this confusion is delirium. In adults, a medication called quetiapine has been effective in treating delirium. This is considered an "off label" use as the FDA has not approved quetiapine for this indication.

Pediatricians have been using quetiapine to treat delirium in children as well, but there is currently no data proving that it is effective in children. This study is being done to determine if quetiapine is effective for the treatment of ICU delirium in children.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Year 至 22 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Any patient in the PICU aged 1 year to 21 years old who is diagnosed with delirium

排除标准

  • Richmond Agitation Sedation Scale (RASS) score of -4 or -5 (deeply sedated or unarousable).
  • current treatment for alcohol withdrawal
  • hepatic encephalopathy
  • pregnancy
  • diagnosis of major depressive disorder or bipolar disorder
  • diagnosis of movement disorder
  • diagnosis of diabetic ketoacidosis
  • baseline QTc >500 milliseconds
  • non-English speaking subjects and/or parent/guardian

研究组 & 干预措施

Quetiapine

Experimental

A randomized group will receive quetiapine as treatment for delirium.

干预措施: quetiapine (Drug)

Placebo

Placebo Comparator

A randomized group will receive placebo, and not quetiapine.

干预措施: Placebo (Other)

结局指标

主要结局

Time to First Resolution of Delirium

时间窗: Within the first 10 days after study enrollment

Participants were screened for delirium daily. This describes the number of days from study drug initiation (either quetiapine or placebo) to first resolution of delirium (defined as a score of less than 9 on teh Cornell Assessment of Pediatric Delirium \[CAPD\]). If delirium did not resolve within the 10 day period, this defaults to 10 days.

次要结局

  • Total ICU Days With Delirium(Within 10 days after study enrollment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验